P1.01-046 Heterogeneity of NSCLC Surgery Exists in Treatment Patterns and Hospital Costs among Different Centers of China, a Study of 5060 Patients: Topic: Prognostic Factors, Treatment

Jian Zhou,Yanguo Liu,Fan Yang,Jun Wang

DOI: https://doi.org/10.1016/j.jtho.2016.11.570

IF: 20.121

2017-01-01

Journal of Thoracic Oncology

Abstract:Lung cancer is the leading cause of death of all tumors in China. But due to imbalanced development of different provinces, the surgical treatments of Non-small cell lung cancer in different areas of China diverse. The Chinese National NSCLC outcome registry was founded in 2013, which covers 17 provinces across China. We analyze the data of 5060 NSCLC patients retrieved from this registry to reveal the imbalanced circumstances. Data of stage I-III patients were obtained from the NSCLC surgical outcome registry, which included 5060 patients who underwent lung resection surgeries from 17 tertiary hospitals nationwide in 2013-2014. Baseline data, surgical treatment pattern parameters, pathology, number of lymph nodes dissected, and total hospital costs. Heterogeneity of quantitative data was analyzed using Kruskal-Wallis test. Among the 5060 patients, the mean age was 59.7, while 3204 were male. Mean pre-op forced expiratory volume in 1 second (FEV1) was 2.23L (P<0.01), FEV1/FVC was 81.8%(P<0.01). 64.6% patients combined with at least one comorbidity. The average diameter of the tumor was 3.28cm(P<0.01). Mean operation time was 181.2 minutes. (P<0.05).The post-operative pathology confirmed 59.8% as adenocarcinoma while 30.2% as squamous carcinoma. Based on the data submitted by different centers, 88.4%(mean,0 to 98.41) patients who were confirmed as stage III patients received adjuvant therapy before surgery(P<0.01). The rate of minimally invasive surgery was 48.1(mean, 8.1 to 94.7)% in different regions(P<0.01). The number of stations of lymph nodes harvested was 5.8(mean, 4.3 to 7.4)(P<0.05). Mean hospital cost was 55070 (mean, 43051 to 69686) RMB(P<0.01).Tabled 1CenterNo. of lymph nodes in lobectomyCost (CNY)VATS %Adjuvant therapy of Stage III%No. of patients submitted16.34686190.299.383826.45289127.598.878834.54751659.084.872945.67087560.350.367655.35174278.998.639267.46540926.110038776.8506968.510029384.8422068.398.6265Total5.95775750.0788.455060 Open table in a new tab The heterogeneity of surgical treatment is quite huge in different centers of China. The baseline status before surgery, pre-operative therapy strategy, surgical technique, and health economic data submitted to the registry showed imbalanced development of NSCLC surgical treatment in different regions of China.